DGAP-Adhoc: Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Investment
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH
07-Jul-2021 / 16:39 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation, "MAR")
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH
Grünwald, 7 July 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) today, via Dermapharm AG, entered into an agreement to acquire an equity investment and new shares in CORAT Therapeutics GmbH, Braunschweig, Germany. Upon the completion of the capital increase, Dermapharm AG acquires 24.9% of the shares in the company, which is developing an antibody drug for treating COVID-19. The drug, which would be used to treat hospitalised patients with moderate to severe symptoms of COVID-19, is currently undergoing testing in a clinical phase Ib/II trial. It has been shown to reduce the viral load (SARS-CoV-2) in the lungs by 99.4%. The parties have agreed to keep the purchase price for the shares confidential.
>End of ad hoc disclosure<
Contact
Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
E-mail: [email protected]
07-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Dermapharm Holding SE |
|
Lil-Dagover-Ring 7 |
|
82031 Grünwald |
|
Germany |
Phone: |
+49 (0)89 64 86-0 |
E-mail: |
[email protected] |
Internet: |
ir.dermapharm.de |
ISIN: |
DE000A2GS5D8 |
WKN: |
A2GS5D |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: |
1216404 |
|
End of Announcement |
DGAP News Service |
1216404 07-Jul-2021 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
467,12 |
572,42 |
700,88 |
793,83 |
942,91 |
1.024,78 |
1.135,35 |
EBITDA1,2 |
108,60 |
139,63 |
168,53 |
184,52 |
354,07 |
344,87 |
287,48 |
EBITDA-Marge3 |
23,25 |
24,39 |
24,05 |
23,24 |
37,55 |
33,65 |
|
EBIT1,4 |
92,12 |
107,51 |
119,51 |
136,85 |
298,47 |
243,69 |
182,89 |
EBIT-Marge5 |
19,72 |
18,78 |
17,05 |
17,24 |
31,65 |
23,78 |
16,11 |
Jahresüberschuss1 |
77,74 |
75,23 |
77,81 |
85,93 |
208,90 |
132,62 |
60,53 |
Netto-Marge6 |
16,64 |
13,14 |
11,10 |
10,82 |
22,16 |
12,94 |
5,33 |
Cashflow1,7 |
86,74 |
159,13 |
100,61 |
131,10 |
250,37 |
288,53 |
219,42 |
Ergebnis je Aktie8 |
1,56 |
1,41 |
1,43 |
1,59 |
3,89 |
2,49 |
1,16 |
Dividende8 |
0,00 |
0,77 |
0,80 |
0,88 |
2,17 |
1,05 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Grant Thornton
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Dermapharm Holding |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2GS5D |
31,950 |
Halten |
1.720,19 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
13,89 |
24,38 |
0,58 |
17,76 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,50 |
7,84 |
1,52 |
9,25 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,05 |
0,88 |
2,75 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
15.05.2024 |
27.08.2024 |
14.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-12,17% |
-19,89% |
-24,54% |
-27,09% |
|
|